Similar articles

• Hormonal treatment of advanced disease: some newer aspects.

  Griffiths K, Eaton CL, Harper ME, Turkes A, Peeling WB. Griffiths K, et al. Semin Oncol. 1994 Oct;21(5):672-87. Semin Oncol. 1994. PMID: 7939755 Review. No abstract available.
• Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

  Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators. Kawakami J, et al. Cancer. 2006 Apr 15;106(8):1708-14. doi: 10.1002/cncr.21799. Cancer. 2006. PMID: 16544313
• [Hormone therapy in prostate cancer: clinical results].

  Morote-Robles J. Morote-Robles J. Rev Esp Fisiol. 1990 Mar;46(1):59-62. Rev Esp Fisiol. 1990. PMID: 1697693 Review. Spanish.
• Androgen deprivation therapy for prostate cancer: current status and future prospects.

  Miyamoto H, Messing EM, Chang C. Miyamoto H, et al. Prostate. 2004 Dec 1;61(4):332-53. doi: 10.1002/pros.20115. Prostate. 2004. PMID: 15389811 Review.
• A critical review of the concept of total androgen ablation in the treatment of prostate cancer.

  Schulze H, Isaacs JT, Coffey DS. Schulze H, et al. Prog Clin Biol Res. 1987;243A:1-19. Prog Clin Biol Res. 1987. PMID: 3309968 Review. No abstract available.